PURPOSE: To evaluate the clinical and biologic safety of superparamagnetic iron oxide (SPIO) as a contrast agent in magnetic resonance (MR) imaging and to assess its efficacy in the detection of liver metastases. MATERIALS AND METHODS: Twenty adults with liver metastases underwent MR imaging at 1.5 T before and 1 hour after infusion of SPIO. Four spin-echo (SE) sequences and one gradient-echo (GRE) sequence were used. RESULTS: There were no adverse reactions. Alterations in serum protein, serum iron, transferrin, and ferritin levels and transferrin saturation coefficient were statistically significant. The mean tumor-to-liver contrast-to-noise ratio (C/N) increased markedly with all sequences. The best postcontrast tumor-to-liver contrast was obtained with the GRE sequence (repetition time msec/echo time msec = 300/15). The mean number of apparent lesions detected after administration of SPIO increased by 12 with the proton-density-weighted SE sequences (800/30 and 2,500/30), four with the T2-weighted SE sequence (2,500/90), and seven with the GRE sequence (300/15). CONCLUSION: SPIO is safe, increases tumor-to-liver C/Ns with some sequences, and improves the detection of liver metastases.
PURPOSE: To evaluate the clinical and biologic safety of superparamagnetic iron oxide (SPIO) as a contrast agent in magnetic resonance (MR) imaging and to assess its efficacy in the detection of liver metastases. MATERIALS AND METHODS: Twenty adults with liver metastases underwent MR imaging at 1.5 T before and 1 hour after infusion of SPIO. Four spin-echo (SE) sequences and one gradient-echo (GRE) sequence were used. RESULTS: There were no adverse reactions. Alterations in serum protein, serum iron, transferrin, and ferritin levels and transferrin saturation coefficient were statistically significant. The mean tumor-to-liver contrast-to-noise ratio (C/N) increased markedly with all sequences. The best postcontrast tumor-to-liver contrast was obtained with the GRE sequence (repetition time msec/echo time msec = 300/15). The mean number of apparent lesions detected after administration of SPIO increased by 12 with the proton-density-weighted SE sequences (800/30 and 2,500/30), four with the T2-weighted SE sequence (2,500/90), and seven with the GRE sequence (300/15). CONCLUSION:SPIO is safe, increases tumor-to-liver C/Ns with some sequences, and improves the detection of liver metastases.
Authors: Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos Journal: Eur Radiol Date: 2004-12-31 Impact factor: 5.315
Authors: Janine Rennert; Ernst-Michael Jung; Andreas G Schreyer; Patrick Hoffstetter; Peter Heiss; Stefan Feuerbach; Niels Zorger Journal: World J Gastroenterol Date: 2011-04-07 Impact factor: 5.742
Authors: Young Kon Kim; Jeong Min Lee; Chong Soo Kim; Gyung Ho Chung; Chan Young Kim; In Hee Kim Journal: Eur Radiol Date: 2004-12-29 Impact factor: 5.315
Authors: Carlo Bartolozzi; Francescamaria Donati; Dania Cioni; Carlo Procacci; Giovanni Morana; Antonio Chiesa; Luigi Grazioli; Giorgio Cittadini; Giuseppe Cittadini; Andrea Giovagnoni; Giovanni Gandini; Jochen Maass; Riccardo Lencioni Journal: Eur Radiol Date: 2003-08-09 Impact factor: 5.315